ClinicalTrials.gg
RecruitingNCT06853496Updated Jul 29, 2025

Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer

A Phase 1 interventional study of RK-582 in Unresectable Colorectal Neoplasm Metastasis, sponsored by Eiji Shinozaki. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Eiji Shinozaki · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Colorectal Neoplasms with a site in Japan — 38 open to participants now, 67 under way, 14 of them phase 3. Colorectal Neoplasms · Japan.

Planned enrollment
132nd of 160
48 · median 198
Started
2025
with 14 others
Phase 1
41 of 174
10 open now
Primary completion
2027-03
later than 13 of 66 live
Registered
155th of 174
by date

Among the 174 studies in Colorectal Neoplasms with a site in Japan, this one is the 132nd largest by planned enrollment of the 160 interventional ones that give a count, is one of 15 that started in 2025, is one of 41 in phase 1, reaches primary completion later than 13 of the 66 other live ones, and was the 155th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

38 of the 174 studies in Colorectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Colorectal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

Tankyrase, the fifth and sixth members of the poly(ADP-ribose) polymerase (PARP) family (PARP-5a/b), is responsible for poly(ADP-ribosyl)ation (PARylation), and was originally identified as a factor that promotes the function of telomerase, an enzyme that elongates telomeres. Subsequently, it was reported that tankyrase enhances Wnt/beta-catenin signaling by PARylation and subsequent degradation of AXIN, a negative regulator of Wnt/beta-catenin signaling, suggesting that tankyrase inhibitors may be a new treatment for colorectal cancer.

RK-582 was discovered through lead optimization from a tankyrase inhibitor that suppresses the growth of human colorectal cancer cells. It was confirmed that RK-582 selectively inhibited tankyrase among the PARP family enzymes, suppressed the growth of Wnt/beta-catenin signal-dependent human colorectal cancer cells at both the levels of cultured cells and xenograft tumors in immunodeficient mice, and accumulated AXIN to decrease beta-catenin and downregulate the target gene expression as pharmacodynamic biomarkers.

Based on these findings, RK-582 is thought to have potential as a new treatment for colorectal cancer patients. At present, however, the efficacy and safety of RK-582 in humans have not been confirmed. Thus, this clinical trial is conducted with the aim of investigating the tolerability and safety of RK-582 for patients with unresectable advanced or recurrent colorectal cancer as a first-in-human trial, in which RK-582 is administered to humans for the first time.

03

Conditions studied

  • Unresectable Colorectal Neoplasm Metastasis

Keywords

  • colorectal neoplasm
  • colorectal cancer
  • tankyrase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically diagnosed colorectal cancer
  • Patients who are or intolerant to standard treatment for unresectable advanced or recurrent colorectal cancer
  • Patients with according to guideline ver 1.1
  • Patients who are able to take capsules orally

Exclusion criteria

Exclusion Criteria:

  • Patients with gastrointestinal, hepatic, musculoskeletal, respiratory, cerebral/cardiovascular, hematologic, oncologic, endocrine, immunologic, psychiatric, neurologic, or genitourinary diseases, or patients with conditions that are judged to threaten the safety of the participant or to affect the outcome of this clinical trial by the investigators
  • Patients with medical history of interstitial lung disease
  • Patients with chronic nausea, vomiting or diarrhea that may interfere with oral administration of the drug
  • Patients with pulmonary embolism or central deep vein thrombosis.
  • Patients receiving treatment with strong inhibitors or inducers.
  • Patients diagnosed and treated for osteoporosis or patients with a bone mineral density of less than T-score -2.5 at the time of screening
  • Patients with obvious bone in the long bones, vertebrae, or other parts of the leg where gravity is applied
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    RK-582

    Drug: RK-582

Interventions

  • DrugRK-582

    Dosing Frequency: Do single dose of RK-582 at the dose level specified for the cohort. Seven days after the first dose, Start repeated daily dose and continue until discontinuation criteria were met. Dose level per dose: Dose Level 1: 5 mg BID Dose level 2: 10 mg QD Dose level 3: 20 mg QD Dose level 4: 40 mg QD Dose Level 5: 60 mg QD Dose Level 6: 80 mg QD Dose Level 7: 100 mg QD Dose Level 8: 200 mg QD

06

What researchers measure

Primary outcomes

  1. Percentage of dose-limiting toxicity

    Time frame: 35 days after the first dose of RK-582

  2. Number of participants with adverse events as assessed by CTCAE v5.0

    Time frame: Approximately 1 year after the first dose of RK-582

Secondary outcomes

  1. Area under the curve (AUC) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  2. Maximum plasma concentration (Cmax) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  3. Maximum concentration time (Tmax) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  4. Elimination rate constant (kel) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  5. Elimination half-life (t1/2) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  6. Apparent total body clearance (CLtot/F) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  7. Apparent volume of distribution (Vd/F) after single or repeated dosing

    Time frame: 22 days after the first dose of RK-582

  8. Objective response rate based on investigator's judgment as assessed by RECIST guideline ver. 1.1

    Time frame: Approximately 1 year after the first dose of RK-582

  9. Percentage of subjects who achieved a complete or partial response on the best overall response as assessed by RECIST guideline ver. 1.1

    Time frame: Approximately 1 year after the first dose of RK-582

  10. Duration of response as assessed by RECIST guideline ver. 1.1

    Time frame: Approximately 1 year after the first dose of RK-582

  11. Disease control rate as assessed by RECIST guideline ver. 1.1

    Time frame: Approximately 1 year after the first dose of RK-582

  12. Time to response as assessed by RECIST guideline ver. 1.1

    Time frame: Approximately 1 year after the first dose of RK-582

  13. Progression-free survival as assessed by RECIST guideline ver. 1.1

    Time frame: Approximately 1 year after the first dose of RK-582

  14. Overall survival

    Time frame: Approximately 30 months after the first dose of RK-582

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 166 non-industry phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 24 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06853496
Lead sponsor
Eiji Shinozaki
Collaborators
Japan Agency for Medical Research and Development
Responsible party
Eiji Shinozaki (Vice Director of Gastroenterological Chemotherapy Department, Japanese Foundation for Cancer Research) — Sponsor-investigator
First posted
Mar 3, 2025
Start date
Mar 13, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 29, 2025

Study contacts

Eiji Shinozaki
Contact
eiji.shinozaki@jfcr.or.jp
+81-3-3520-0111
Kensei Yamaguchi
study chair · Cancer Institute Hospital of JFCR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion